"Making changes at the DNA level and creating proteins with all kinds of possibilities feels really empowering to me, and that is what I do at Genentech. I feel grateful for leading a protein engineering group at the birthplace of the recombinant DNA technology, knowing that our collective efforts have an impact on patients’ lives."
My background is in protein engineering, and I engineered various domains, including enzymes and stimulus-responsive peptides during my graduate studies at Columbia University, to serve as building blocks in biotechnology applications.
During my postdoc at Harvard Medical School & Massachusetts General Hospital, I was awarded the NIH Ruth L. Kirschstein Fellowship and conducted studies in the areas of protein engineering, synthetic biology, genetic, and tissue engineering.
At Genentech, my research group develops protein-based therapeutics for patients in need and we are part of the Large Molecule Drug Discovery Organization. We collaborate with many other groups in the Research Organization, and I feel lucky to be surrounded by top-notch scientists from all over the world.
At Genentech, I lead a research group focusing on protein engineering and large molecule drug discovery for therapies in different therapeutic areas, including neuroscience and cancer immunology. In my lab, we engineer a variety of different proteins and also develop technologies to be used in gene therapy.